VIP 6MG

VIP 6MG

$89.00

VIP is a neuropeptide that reduces inflammation and regulates the immune system. It shows promise in treating neurodegenerative diseases and fibrosis-related conditions, offering potential benefits for cognitive function. Additionally, VIP may aid in managing mold toxicity by mitigating systemic and neuro-inflammatory responses.

50 in stock (can be backordered)

Quantity Discount / Amount Price
3 4% $85.44
5 8% $81.88
10 11% $79.21
Summary
VIP 6MG$89.00
$89.00

Product Usage: This product is designated as a "Novelty Peptide" and is intended solely for specialized applications in controlled settings. It is not intended for any specific biological, therapeutic, or diagnostic use. All information provided on this website is for informational and educational purposes only and should not be construed as guidance for any particular application or usage.

download

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide that belongs to the secretin/glucagon superfamily. It is widely distributed throughout the body, including the central and peripheral nervous systems, gastrointestinal tract, and immune system. VIP plays crucial roles in various physiological processes, including vasodilation, smooth muscle relaxation, neurotransmission, and immunomodulation. It exerts its effects primarily through binding to two G protein-coupled receptors: VPAC1 and VPAC2.

Sequence: His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2

Molecular Formula: C147H238N44O42S

Molecular Weight: 3325.8 g/mol

CAS Number: 37221-79-7

  1. Neuroprotection: VIP has demonstrated neuroprotective effects in various models of neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
  2. Anti-inflammatory Properties: Studies have shown that VIP possesses potent anti-inflammatory and immunomodulatory effects, potentially beneficial in treating inflammatory conditions such as rheumatoid arthritis and inflammatory bowel disease.
  3. Immunoregulatory Properties: Studies have shown that VIP can help mitigate chronic inflammation caused by mold exposure. Mold toxins trigger an overactivation of the immune system, leading to systemic inflammation. VIP can suppress pro-inflammatory cytokines (e.g., TNF-α, IL-6) and increase regulatory T-cell activity, helping restore immune balance in affected individuals.
  4. Cardiovascular Effects: VIP acts as a potent vasodilator and has been implicated in regulating blood pressure and cardiac function.
  5. Gastrointestinal Function: In the digestive system, VIP regulates motility, secretion, and blood flow, playing a role in maintaining intestinal homeostasis.
  6. Circadian Rhythm Regulation: VIP is crucial for maintaining synchronization among neurons in the suprachiasmatic nucleus, the brain's primary circadian pacemaker.

  1. Therapeutic Applications: Further investigation into the potential use of VIP or its analogs in treating neurodegenerative diseases, inflammatory conditions, and cardiovascular disorders.
  2. Delivery Methods: Research into novel delivery systems to overcome the short half-life of VIP in vivo and improve its therapeutic efficacy.
  3. Receptor-Specific Agonists: Development of VPAC1 or VPAC2 receptor-specific agonists to target specific physiological effects while minimizing side effects.
  4. Long-term Safety: Extended studies to evaluate the long-term effects and safety profile of VIP-based therapies, particularly in diverse patient populations.
  5. Combination Therapies: Exploration of potential synergistic effects of VIP with other therapeutic agents in various disease models.

  1. Harmar, A.J., et al. (2012). "Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR Review 1." British Journal of Pharmacology, 166(1), 4-17. [Online].
    Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415625/
  2. Delgado, M., et al. (2004). "Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity." Cellular and Molecular Biology, 50(6), 645-660. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/15559977/
  3. Gozes, I., et al. (2020). "The promise of VIP-based drugs: From the nose to the brain." Journal of Molecular Neuroscience, 70(5), 671-675. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/32060697/
  4. Moody, T.W., et al. (2011). "VIP and PACAP: Recent insights into their functions/roles in physiology and disease from molecular and genetic studies." Current Opinion in Endocrinology, Diabetes and Obesity, 18(1), 61-67. [Online].
    Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150729/
  5. Abad, C., et al. (2012). "Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease." Gastroenterology, 141(6), 2166-2176. [Online].
    Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3221070/
  6. Waschek, J.A. (2013). "VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair." British Journal of Pharmacology, 169(3), 512-523. [Online].
    Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682698/
Vasoactive Intestinal Peptide (VIP) represents a promising avenue for various therapeutic applications due to its diverse physiological effects. As research progresses, VIP and its analogs may offer new treatment options for neurodegenerative, inflammatory, and cardiovascular disorders. However, as with all peptide therapies, it is important to approach VIP-based treatments with caution, and their potential benefits and risks require ongoing evaluation through long-term clinical studies and further research. VIP peptide also shows great potential as a therapeutic option for mold toxicity and CIRS due to its powerful anti-inflammatory and immunomodulatory effects. Its ability to regulate brain function, restore hormonal balance, and correct gene expression abnormalities makes it a valuable tool in the management of patients suffering from biotoxin illnesses like mold exposure.